The Harvard Drug Group LLC Initiates Nationwide Recall of Gabapentin Capsules Due to Impurity Concerns
The Harvard Drug Group LLC has initiated a Class II nationwide recall of Gabapentin Capsules, USP, 100 mg, due to out-of-specification impurity levels identified during stability testing. This voluntary action impacts multiple lots, necessitating immediate review by procurement and regulatory teams to assess supply chain stability and ensure patient safety. The event underscores the critical need for robust quality control in pharmaceutical distribution.
FDA-Initiated Recall: Gabapentin Capsules Fail Impurity Specifications
The Harvard Drug Group LLC, based in Dublin, OH, has initiated a Class II voluntary recall of multiple lots of Gabapentin Capsules, USP, 100 mg. This critical action, designated recall number D-0031-2026, commenced on October 10, 2025, and remains ongoing. The primary reason for the recall is the product's failure to meet established impurity and degradation specifications. Specifically, routine stability testing revealed an out-of-specification (OOS) result for the highest unknown impurity, indicating a potential quality compromise over time. For procurement directors, this means an immediate need to quarantine and return affected product. The recall impacts Gabapentin Capsules, USP, 100 mg, distributed nationwide across the U.S. under various NDC codes, including 0904-6665-61 (blister pack) and 55154-3363-0 (outer bag), among others. Several critical lots are implicated: M04989A (Bag) / M04989 (Blister Pack) with an expiration date of February 2026; M05056A (Bag) / M05056 (Blister Pack) expiring April 2026; M05150A (Bag) / M05150 (Blister Pack) expiring July 2026; and both M05312A (Bag) / M05312 (Blister Pack) and M05342A (Bag) / M05342 (Blister Pack), both expiring January 2027. Regulatory affairs heads must ensure all internal and external stakeholders are informed and that proper procedures for managing recalled product are rigorously followed to mitigate patient risk and maintain compliance.
Market Impact and Supply Chain Vulnerabilities for Gabapentin
Gabapentin, a widely used generic drug classified as a human prescription drug, is primarily indicated for conditions involving decreased central nervous system disorganized electrical activity. The nationwide distribution pattern of The Harvard Drug Group LLC's recalled Gabapentin Capsules means that this event has broad implications for the U.S. pharmaceutical supply chain. Business development executives and supply chain VPs must immediately assess their exposure to this specific product and its potential impact on patient access and market stability. While The Harvard Drug Group LLC initiated this recall, the FDA's openfda data also lists Major Pharmaceuticals and Cardinal Health 107, LLC as manufacturers associated with Gabapentin products under similar NDC ranges (e.g., 0904-6665, 55154-3363). This indicates a complex manufacturing and distribution network for generic Gabapentin. Procurement teams should investigate whether these other entities are affected by similar quality issues or if they can serve as immediate alternative suppliers to prevent potential shortages. The Class II classification suggests that while the health consequences may be temporary or reversible, the disruption to patient therapy and the need for rapid replacement stock is significant. This event highlights the critical importance of supplier diversification and robust qualification processes for generic drug components and finished products.
Broader Regulatory Scrutiny and Quality Control Imperatives
This voluntary Class II recall of Gabapentin Capsules by The Harvard Drug Group LLC underscores the U.S. FDA's persistent and stringent focus on pharmaceutical quality and manufacturing integrity. While the firm initiated the recall, the underlying issue of out-of-specification impurities during stability testing points to a critical lapse in quality control systems. For regulatory affairs heads, this event serves as a stark reminder that even voluntary actions are subject to intense agency oversight and can trigger deeper investigations into a firm's quality management processes. This incident is not isolated within the broader regulatory landscape. Recent parallel events, such as the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026 due to sterility assurance failures, or the FDA hearing concerning Amgen's Tavneos market future, illustrate a heightened regulatory environment across the life sciences industry. These events collectively signal that the FDA is actively monitoring and enforcing quality standards, from impurity profiles to sterility. Companies must proactively invest in robust quality management systems, comprehensive stability programs, and continuous analytical testing to prevent similar issues. Failure to do so not only risks product recalls and market disruption but also invites intensified regulatory scrutiny and potential enforcement actions, impacting business continuity and market reputation.